Embecta Corp.

NasdaqGS EMBC

Embecta Corp. EBIT Margin for the Trailing 12 Months (TTM) ending December 31, 2024: 16.39%

Embecta Corp. EBIT Margin is 16.39% for the Trailing 12 Months (TTM) ending December 31, 2024, a 6.31% change year over year. EBIT ratio is the ratio of EBIT to revenue, measuring a company's operating profitability without considering non-operating income or expenses.

Embecta Corp. EBIT Margin for the Trailing 12 Months (TTM) ending December 31, 2023 was 15.41%, a -37.55% change year over year.
Embecta Corp. EBIT Margin for the Trailing 12 Months (TTM) ending December 31, 2022 was 24.68%, a -40.07% change year over year.
Embecta Corp. EBIT Margin for the Trailing 12 Months (TTM) ending December 31, 2021 was 41.18%.

Key data

Date	EBIT Margin	EPS (Basic)	EPS (Diluted)	Shares (Basic, Weighted)

NasdaqGS: EMBC

Embecta Corp.

CEO	Mr. Devdatt Kurdikar
IPO Date	March 22, 2022
Location	United States
Headquarters	300 Kimball Drive
Employees	2,200
Sector	Healthcare
Industries Pharmaceuticals Drugstores & Retail Pharmacies Eyewear Medical Instruments Non-Alcoholic Beverages Personal Care Snack Foods Soft Drinks & Sodas

Description

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications to assist people with managing their diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is based in Parsippany, New Jersey. Embecta Corp.(NasdaqGS:EMBC) operates independently of Becton, Dickinson and Company as of April 1, 2022.

Key trends

Past 5 years